Patient Community Day at MSToronto2026 MStranslate November 6, 2026 Community, ECTRIMS, Events, Research Today, we are pleased to share recordings of the Patient Community Day event held at the conclusion of MSToronto2026. Patient Community Day has been built upon the strong belief that progress in multiple...
The ECTRIMS Podcast at MSToronto2026 MStranslate November 5, 2026 Conferences, ECTRIMS, Research 1 Comment The MStranslate team had the privilege of attending MSToronto2026, the 10th joint Congress co-hosted by the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) and the European...
Antiviral Reverses Disability in Mouse Model of MS MStranslate September 28, 2026 Research, Treatments Research Summary: The nucleoside analog kamuvudine-9 shows protective and therapeutic efficacy in a mouse model of multiple sclerosis While we now have a number of treatments for multiple sclerosis (MS),...
Assessing & Monitoring Cognition in MS MStranslate August 11, 2026 Cognition, Research MStranslate's recent communications collaboration with Multiple Sclerosis Auckland delivered an opportunity for our Co-founder, Brett Drummond, to author a contribution for the Winter 2026 edition of their...
Potential Changes to MS Treatment Access in Australia MStranslate July 2, 2026 Treatments Members of the Australian multiple sclerosis community are likely aware of media reports that two key MS medications, Ocrevus and Kesimpta, are at risk of being withdrawn from the Australian Government’s...
MS Auckland Webinar: AHSCT as a Treatment for MS MStranslate June 18, 2026 Research, Stem Cells, Treatments The second episode of an MS Auckland webinar series that MStranslate has been participating in was on the topic of Autologous Haematopoietic Stem Cell Transplant (AHSCT) as a treatment for multiple...
MS Auckland Webinar: Remyelination Research in MS MStranslate April 15, 2026 Cambridge, Remyelination, Research Recently, MStranslate had the pleasure of participating in a Multiple Sclerosis Auckland webinar to discuss advances in myelin repair research in multiple sclerosis. Our Co-founder, Brett Drummond, was...
FDA Decision On Tolebrutinib MStranslate January 12, 2026 Clinical Trials Last week, we posted on Facebook that the FDA has decided to not approve tolebrutinib for the treatment of secondary progressive multiple sclerosis, despite positive Phase 3 trial results. In this article,...
Multiple Sclerosis Research In 2026 MStranslate January 5, 2026 Progressive MS, Remyelination, Treatments 4 Comments 2026 is upon us! As fireworks ring out around the world to usher in the new year, we like to look ahead and think about what new developments we might see in multiple sclerosis research over the coming 12...
Revisiting ECTRIMS Congress 2025 MStranslate November 18, 2025 ECTRIMS, Podcasts, Research Between September 23 and 26, 2025, the 41st annual ECTRIMS Congress took place in Barcelona, Spain, co-convened by the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and...